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Ph-like acute lymphoblastic leukemia (ALL) is a novel subgroup of high-risk childhood ALL. In this issue of
Cancer Cell, Roberts et al. describe the identification of genetic alterations that lead to activated kinase
and cytokine receptor signaling in Ph-like ALL and demonstrate that this aberrant signaling can be inhibited
effectively.The improving survival rate for children
with acute lymphoblastic leukemia (ALL)
is one of the greatest success stories of
cancer treatment. However, a small pro-
portion of patients will relapse; relapsed
disease has a poor response to current
therapy, resulting in reduced survival.
Thus, to ensure optimum treatment, it
is essential that patients at high-risk of
relapse are identified at the time of
diagnosis.
The prognostic relevance of specific
chromosomal abnormalities in B-lineage
ALL has been known for some time. To
date, this information remains an impor-
tant factor in risk stratification of these
patients for treatment (Moorman et al.,
2010). Inparticular, patientswith the trans-
location, t(9;22)(q34;q11.2), resulting in
the BCR-ABL1 fusion, known as Philadel-
phia chromosome (Ph)-positive ALL, with
rearrangements of the MLL gene, or with
hypodiploidy (<40 chromosomes) are
stratified as high-risk and treated on inten-
sive therapy. More recently, using fluores-
cence in situ hybridization and genomic
approaches, novel genetic aberrations
have been identified, including those
leading to dysregulated expression of
CRLF2 or those targeting genes involved
in transcriptional regulation of lymphoid
development (Mullighan et al., 2007,
2009a; Russell et al., 2009). It was noted
that alterations of one of these genes,
IZKF1, was strongly associated not only
with the poor-riskPh-positiveALL but also
with poor-risk among Ph-negative ALL.
Many of these Ph-negative cases show a
gene expression profile similar to that of
the Ph-positive ALL and share the same
high-risk of relapse and poor outcome.
These cases of ALL were defined as
BCR-ABL1-like or Ph-like (Den Boeret al., 2009; Mullighan et al., 2009b) and
account for 10% of childhood B-ALL. A
pattern of genetic aberrations was begin-
ning to emerge among these Ph-like ALL
to facilitate their identification in the
manystudygroups forwhichgeneexpres-
sion profiling is not available. In addition to
the high incidence of IKZF1 deletions,
another genomic pointer of Ph-like ALL
so far identified is dysregulated CRLF2
expression. This abnormality is present in
50% of Ph-like cases, of which 50%
also harbor Janus kinase (JAK) mutations.
However, in the remaining cases, the
genetic alterations were unknown.
In the paper by Roberts and colleagues
in this issue of Cancer Cell (Roberts et al.,
2012), the authors provide a comprehen-
sive genomic definition of Ph-like ALL
with genetic alterations of a range of
kinase and cytokine receptors. Initially,
transcriptome and whole genome se-
quencing approaches were used to inter-
rogate the genomes of 15 Ph-like cases.
The altered genes discovered from this
analysis included previously reported,
albeit rarely, and novel fusions and muta-
tions: for example ABL1, including the
NUP214-ABL1 fusion that had been previ-
ously shown to be amplified in T-ALL,
EPOR, JAK2,PDGFRb, EBF1, FLT3, IL7R,
and SH2B3. Largely, these genes facili-
tate leukemic transformation by inducing
constitutive kinase activation and signal-
ing through the Ras and JAK/STAT5 path-
ways. All 15 cases showed at least one of
these abnormalities (Figures 1A and 1B),
indicating that more extensive screening
would be required to determine a more
accurate incidence as well as the distribu-
tion of these alterations. A range of tech-
niques was then applied to screen an
extended high-risk cohort from theCancer Cell 22Children’s Oncology Group. The same
types of aberrations were identified, and
their estimated incidence is shown in
Figure 1C.
Although a range of aberrations were
identified in Ph-like ALL, the activation of
ABL1 and/or JAK/STAT signaling path-
ways was the common mechanism for
transformation. An exciting observation
was that the transformation induced by
these alterations was attenuated by tyro-
sine kinase inhibitors (TKI). The basal level
of substrate phosphorylation as deter-
mined by phosphoflow cytometry was
reduced by several TKI in two primary
patient samples harboring the NUP214-
ABL1 fusion and by a JAK2 inhibitor in
two JAK2 rearranged samples. In addi-
tion, the therapeutic efficacy of the JAK2
inhibitor, ruxolitinib, was demonstrated
in a xenograft model of a JAK2 rearranged
primary ALL sample. Another xenograft
model of a human B-ALL harboring both
an IL7R activating mutation and deletion
of SH2B3 responded to ruxolitinib. Also
of interest was that a NUP214-ABL1 ALL
xenograft model responded to the ABL1
inhibitor, dasatinib, confirming that cells
expressing NUP214-ABL1 are sensitive
to TKI within both T- and B-lineage ALL.
TKI treatment in addition to chemo-
therapy has led to dramatic improvements
in outcome for Ph-positive ALL patients
(Schultz et al., 2009). Patients with
PDGFRb rearrangements show complete
hematological and molecular response to
imatinib (Apperley et al., 2002). It had
been shown previously that B-ALL cells
harboring CRLF2 rearrangements have
enhanced signaling through oncogenic
pathways that can be targeted with JAK
or P13K inhibitors (Tasian et al., 2012).
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Figure 1. Distribution of Rearrangements, Mutations,
and Deletions Affecting Kinase and Cytokine Signaling
(A and B) Distribution of rearrangements (A), mutations, and
deletions (B) among the 15 discovery Ph-like ALL patients
described in Roberts et al. (2012). The rearrangements of
ABL1 include two cases of NUP214-ABL1. The IKZF1 cate-
gory includes deletions and mutations; two mutations
occurred along with deletions. The CDKN2A/CDKN2B cate-
gory includes deletions only. The remaining aberrations are
mutations. The distribution is an estimate as some patients
harbored more than one of these aberrations.
(C) Estimated distribution of aberrations among Ph-like
ALL calculated from Children’s Oncology Group high-risk
cohorts. In these high-risk cohorts 15%–20% of patients
were classified as Ph-like according to their gene expression
signature. In total, 50% of cases had CRLF2 high expres-
sion, of which 30% have JAK2 mutations. The ‘‘Other’’
category includes an estimated incidence of ABL1, JAK2,
PDGFRb, and other kinase rearrangements and sequence
mutations.
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Previewsthat Ph-like leukemic cells are sensi-
tive to currently available TKI. Thus,
taken together, these observations
indicate that screening at diagnosis
to identify those Ph-like patients
who may benefit from the addition
of TKI to their current treatment
regimen would be a feasible
proposition.
At present, gene expression
profiling, next generation sequenc-
ing, as well as the range of complex
molecular techniques required to
reliably identify the specific genetic
alterations described in the Roberts
et al. (2012) paper are not routinely
available in most diagnostic labora-
tories and will no doubt preclude
widespread screening for these
cases in the near future. However,
with the rising implementation of
flow cytometry in the diagnostic
arena and the increased application
of phosphoflow cytometry world-
wide, it may be possible to integrate
flow cytometric phosphosignaling
analysis for activated kinase path-
ways in conjunction with flow cyto-
metric detection of CRLF2 overex-
pression as a diagnostic test to
identify Ph-like cases.
Alternatively, bymaking use of the
distinctive gene expression profile
of Ph-like ALL, it may become
possible to design customized tar-
geted low density gene expression
arrays suitable for routine diagnostic
use. Such arrays would serve as the
initial screen for Ph-like ALL, fol-
lowed by testing for the specific
alterations in kinase and cytokine
receptors. These patients could
then be considered for treatment
combining chemotherapy with ap-
propriate TKI, thus improving the
outcome for another group of high-
risk childhood ALL patients.140 Cancer Cell 22, August 14, 2012 ª2012 Elsevier Inc.REFERENCES
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